

NOTICE
NATIONAL INSTRUMENT 51-102
CHANGE IN CORPORATE STRUCTURE

This notice is provided pursuant to the requirements of Section 4.9 of National Instrument 51-102 – *Continuous Disclosure Obligations*.

Item 1: Names of the Parties to the Transaction

Westcot Ventures Corp. (“**Westcot**”) and WPD Pharmaceuticals LLC (“**WPD Poland**”).

Item 2: Description of the Transaction

On December 20, 2019, Westcot and WPD closed a Share Exchange Agreement, pursuant to which Westcot acquired all the issued and outstanding shares of WPD Poland and changed its name to “**WPD Pharmaceuticals Inc.**” (“**WPD**”).

Item 3. Effective Date of the Transaction

December 20, 2019.

Item 4. Names of Each Party That Ceased to be a Reporting Issuer Subsequent to the Transaction and of Each Continuing Entity

WPD continues to be a reporting issuer in the Provinces of British Columbia, Alberta, and Ontario.

Item 5. Date of the Reporting Issuer’s First Financial Year-End Subsequent to the Transaction

The first financial year end of WPD became December 31, 2019.

Item 6. Periods, Including the Comparative Periods, if any, of the Interim and Annual Financial Statements Required to be Filed For The Reporting Issuer’s First Financial Year Subsequent To The Transaction

Not applicable.

Item 7. Documents Which Were Filed Under National Instrument 51-102 that Describe the Transaction and Where Those Documents Can Be Found In Electronic Format

- News Release dated July 17, 2019, filed on July 17, 2019
- News Release dated December 23, 2019, filed on December, 2019
- News Release dated January 8, 2020, filed on January 8, 2020
- Listing Statement dated December 20, 2019 filed on December 27, 2019

Each of the foregoing is available under the profile of the Company at www.sedar.com.

Item 8. Date of Report

June 11, 2020.

WPD PHARMACEUTICALS INC.

“Christopher Cherry”

Christopher Cherry
Chief Financial Officer